Browsing by author "Morden, James Peter"
Now showing items 1-6 of 6
-
Accelerated versus standard epirubicin followed by CMF versus capecitabine as adjuvant therapy of breast cancer: results of the randomised UK TACT2 trial (CRUK/05/19)
Bliss, J; banerji, J; Gillman, A; Morden, J -
ART DECO (CRUK/10/018): dose escalated vs standard dose IMRT in locally advanced head and neck cancer
Nutting, C; Morden, J; Bernstein, D; Beasley, M; Cosgrove, V; et al. (ELSEVIER IRELAND LTD, 2017-03-01) -
Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study.
Latimer, NR; Abrams, KR; Lambert, PC; Morden, JP; Crowther, MJ (2018-03)When patients randomised to the control group of a randomised controlled trial are allowed to switch onto the experimental treatment, intention-to-treat analyses of the treatment effect are confounded because the separation ... -
COSTAR trial results: 3-D Conformal Radiotherapy vs Cochlea-Sparing IMRT in parotid cancer patients
Nutting, C; Morden, J; Beasley, M; Bhide, S; Emson, M; et al. (ELSEVIER IRELAND LTD, 2017-03-01) -
The Application and Feasibility of Using Routine Data Sources for Long-term Cancer Clinical Trial Follow-up.
Bhattacharya, IS; Morden, JP; Griffin, C; Snowdon, C; Brannan, R; et al. (2017-12) -
The UK plasma based molecular profiling of advanced breast cancer to inform therapeutic choices (plasmamatch) trial: a multiple parallel cohort, open-label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening (CRUK/15/010)
Bliss, J; Kernaghan, S; Fribbens, C; Stevenson, L; Morden, J; et al. (BIOMED CENTRAL LTD, 2017-05-08)